Optimal Lymph Node Yield for Survival Prediction in Rectal Cancer Patients After Neoadjuvant Therapy

doi:10.2147/CMAR.S328666

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 化妝品應用與管理系(所) > 期刊論文 > Item 310902800/34518

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34518

標題:	Optimal Lymph Node Yield for Survival Prediction in Rectal Cancer Patients After Neoadjuvant Therapy
作者:	Lin, Yu-Min Chou, Chia-Lin Kuo, Yu-Hsuan Wu, Hung-Chang Tsai, Chia-Jen Ho, Chung-Han Chen, Yi-Chen Yang, Ching-Chieh Lin, Cheng-Wei
貢獻者:	Chi Mei Med Ctr, Dept Internal Med, Div Hepatogastroenterol Chi Mei Med Ctr, Dept Surg, Div Colorectal Surg Chung Hwa Univ Med Technol, Dept Med Lab Sci & Biotechnol Chi Mei Med Ctr, Dept Internal Med, Div Hematol & Oncol Chia Nan Univ Pharm & Sci, Dept Cosmet Sci Chia Nan Univ Pharm & Sci, Dept Pharm Chi Mei Med Ctr, Dept Radiat Oncol Chi Mei Med Ctr, Dept Med Res Southern Taiwan Univ Sci & Technol, Dept Informat Management Taipei Med Univ, Coll Med, Sch Med, Dept Biochem & Mol Cell Biol Taipei Med Univ, Coll Med, Grad Inst Med Sci Taipei Med Univ, Wan Fang Hosp, Cell Physiol & Mol Image Res Ctr
關鍵字:	rectal cancer neoadjuvant therapy lymph node yield quality survival
日期:	2021
上傳時間:	2023-11-11 12:00:34 (UTC+8)
出版者:	DOVE MEDICAL PRESS LTD
摘要:	Purpose: A lymph node (LN) yield >12 is required to for accurate determination of nodal status for colorectal cancer but cannot always be achieved after neoadjuvant therapy. This study aims to determine the difference in LN yield from rectal cancer patients treated with and without neoadjuvant therapy and the effects of specific LN yields on survival. Patients and Methods: The study cohort included a total of 4344 rectal cancer patients treated between January 2007 and December 2015, 2260 (52.03%) of whom received neoadjuvant therapy. Data were retrieved from the Taiwan nationwide cancer registry database. The minimum acceptable LN yield below 12 was investigated using the maximum area under the ROC curve. Results: The median LN yield was 12 (8-17) for patients who received neoadjuvant therapy and 17 (13-24) for those who did not. The recommended LN yield >12 was achieved in 82.73% of patients without and 57.96% of those with neoadjuvant therapy (p < 0.0001). Patients with LN yield >12 had a higher OS probability than did those with LN <12 (OR, 1.33; 95% CI, 1.06-1.66; p = 0.0124). However, the predictive accuracy for survival was greater for LN yield >10 (AUC, 0.7767) than cut-offs of 12, 8, or 6, especially in patients with pathologically-negative nodes (AUC, 0.7660). Conclusion: Neoadjuvant therapy significantly reduces the LN yield in subsequent surgery. A lower yield (LN > 10) may be adequate for nodal evaluation in rectal cancer patients after neoadjuvant therapy.
關聯:	CANCER MANAG RES, v.13, pp.8037-8047
显示于类别:	[化妝品應用與管理系(所)] 期刊論文 [藥學系(所)] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
CMAR.S328666.pdf		3825Kb	Adobe PDF	107	检视/开启
index.html		0Kb	HTML	177	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....